subscribeSubscribe
Enanta Pharma Announces Sale of a Portion of Global Royalties on MAVYRET

Enanta Pharma Announces Sale of a Portion of Global Royalties on MAVYRET
BUSINESSWIRE
25 Apr 2023
Share Share
Enanta Pharmaceuticals Doses First Subject in a Phase 1 Study of EDP-323

Enanta Pharmaceuticals Doses First Subject in a Phase 1 Study of EDP-323
BUSINESSWIRE
17 Oct 2022
Share Share
EU Marketing Authorisation change for Maviret

EU Marketing Authorisation change for Maviret
Anna Smith PHARMA TIMES
09 Mar 2020
Share Share
AbbVie gets positive CHMP opinion for Maviret to shorten treatment

AbbVie gets positive CHMP opinion for Maviret to shorten treatment
PHARMABIZ
03 Feb 2020
Share Share
AbbVie Receives Positive CHMP Opinion for MAVIRET® (glecaprevir/pibrentasvir)

AbbVie Receives Positive CHMP Opinion for MAVIRET® (glecaprevir/pibrentasvir)
PR NEWSWIRE
31 Jan 2020
Share Share
FDA clears shorter treatment regimen for AbbVie`s hep C treatment

FDA clears shorter treatment regimen for AbbVie`s hep C treatment
Jason Mast ENDPTS
30 Sep 2019
Share Share
AbbVie’s HCV treatment receives first for shorter treatment cycle

AbbVie’s HCV treatment receives first for shorter treatment cycle
B. Hargreaves IN-PHARMATECHNOLOGIST
30 Sep 2019
Share Share
US FDA approves AbbVie `s Mavyret to shorten treatment duration

US FDA approves AbbVie `s Mavyret to shorten treatment duration
PHARMABIZ
28 Sep 2019
Share Share
AbbVie Receives FDA Approval of MAVYRET® (glecaprevir/pibrentasvir)

AbbVie Receives FDA Approval of MAVYRET® (glecaprevir/pibrentasvir)
PR NEWSWIRE
27 Sep 2019
Share Share
FDA approves treatment for adults and children with all genotypes of hepatitis C

FDA approves treatment for adults and children with all genotypes of hepatitis C
FDA
27 Sep 2019
Share Share